case_images: PMC4877000_01
case_images: Dynamics of total and mutated BCR-ABL1 transcript levels.. (A) Patient no 1: The patient achieved MMR on solo IFN-alpha and maintained MMR for 88 months; the T315I mutation was persistently undetectable for 62 months due to the overall low levels of total BCR-ABL1 transcripts. (B) Patient no 2: Compound mutations M351T/F317L (100%) developed after sequential therapy with imatinib and dasatinib. The patient has now been on IFN-alpha/nilotinib therapy with undetectable mutations for 29 months. MR5 was achieved on the 15th month of the combined treatment. (C) Patient no 3: Poor compliance to imatinib treatment within the 24th- 30th month; the T315I mutation burden decreased on solo IFN-alpha therapy down to undetectable levels after the combination of IFN-alpha and nilotinib. The patient achieved MR5 in the 22nd month from IFN-alpha treatment initiation. (D) Patient no 4: The T315I mutation decreased on solo IFN-alpha therapy and was not detected for the subsequent 46 months on solo nilotinib therapy. The relatively slow reduction of the BCR-ABL1 transcript level and MMR achievement might have been caused by a problematic compliance to nilotinib. (E) Patient no 5: The T315I mutation decreased on solo IFN-alpha therapy, but the F317L and E255V mutations appeared and expanded. Death of this patient was related to lung tuberculosis. (F) Patient no 6: IFN-alpha therapy did not contribute to the T315I reduction and response improvement. Therefore, the patient has been switched to ponatinib with CCgR achievement after 7 months from ponatinib treatment initiation. IMA-imatinib, NILO-nilotinib, DASA-dasatinib, IFN-alpha -interferon alpha, HU-hydroxyurea, PONA-ponatinib. Note: A mutation burden of 0% represented undetectable levels of mutated BCR-ABL1 transcripts when the sequencing depth was 1,000 to 8,000 sequence reads per each nucleotide position.
case_images: pone.0155959.g001.jpg
case_images: PMC4877000_01_pone.0155959.g001.jpg
case_images: pone.0155959.g001
case_images: T315I mutation levels were reduced from 100% to 4% in patient no 5 (Fig 1), but two other mutations appeared (F317L and E255V). This 85-year old patient died of lung tuberculosis with an overall survival of 44 months. The concept of TKI cessation and IFN-alpha introduction did not contribute to the T315I reduction or to response improvement in patient no 6 (Fig 1).